Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001873919-25-000001
Filing Date
2025-02-13
Accepted
2025-02-13 06:25:21
Documents
1
Period of Report
2025-02-10

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 7080
  Complete submission text file 0001873919-25-000001.txt   8983
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Issuer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 160 PAULSON RD. WABAN MA 02468
Business Address
Aguilar Laura K. (Reporting) CIK: 0001873915 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40629 | Film No.: 25617069

Mailing Address 160 PAULSON RD. WABAN MA 02468
Business Address
Aguilar-Cordova Estuardo (Reporting) CIK: 0001873919 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40629 | Film No.: 25617070